|
1.
|
Volz A, Weiss E, Trowsdale J and Ziegler
A: Presence of an expressed beta-tubulin gene (TUBB) in the HLA
class I region may provide the genetic basis for HLA-linked
microtubule dysfunction. Hum Genet. 93:42–6. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Séve P and Dumontet C: Class III beta
tubulin expression in non-small cell lung cancer. Rev Mal Respir.
27:383–386. 2010.(In French).
|
|
3.
|
Jeon TY, Han ME, Lee YW, et al:
Overexpression of stathmin1 in the diffuse type of gastric cancer
and its roles in proliferation and migration of gastric cancer
cells. Br J Cancer. 102:710–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Gan L, Guo K, Li Y, et al: Up-regulated
expression of stathmin may be associated with hepatocarcinogenesis.
Oncol Rep. 23:1037–1043. 2010.PubMed/NCBI
|
|
5.
|
Yuan SF, Chen WJ, Zhu LJ, et al: Effects
of monoclonal antibodies against human stathmin combined with
paclitaxel on proliferation of the QG-56 human lung carcinoma cell
line. Asian Pac J Cancer Prev. 13:2967–2971. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Eastham LL, Mills CN and Niles RM:
PPARalpha/gamma expression and activity in mouse and human
melanocytes and melanoma cells. Pharm Res. 25:1327–1333. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Olaussen KA, Dunant A, Fouret P, et al:
DNA repair by ER-CC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Bepler G, Kusmartseva I, Sharma S, et al:
RRM1-modulated in vitro and in vivo efficacy of gemcitabine and
platinum in non-small cell lung cancer. J Clin Oncol. 24:4731–4737.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Papadaki C, Tsaroucha E, Kaklamanis L, et
al: Correlation of BRCA1, TXR1 and TSP1 mRNA expression with
treatment outcome to docetaxel-based first-line chemotherapy in
patients with advanced/metastatic non-small-cell lung cancer. Br J
Cancer. 104:316–323. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Papadaki C, Sfakianaki M, Ioannidis G, et
al: ERCC1 and BRAC1 mRNA expression levels in the primary tumor
could predict the effectiveness of the second-line cisplatin-based
chemotherapy in pretreated patients with metastatic non-small cell
lung cancer. J Thorac Oncol. 7:663–671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Reynolds C, Obasaju C, Schell MJ, et al:
Randomized phase III trial of gemcitabine-based chemotherapy with
in situ RRM1 and ERCC1 protein levels for response prediction in
non-small-cell lung cancer. J Clin Oncol. 27:5808–5815. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Mariani M, Shahabi S, Sieber S, Scambia G
and Ferlini C: Class III β-tubulin (TUBB3): more than a biomarker
in solid tumors? Curr Mol Med. 11:726–731. 2011.
|
|
13.
|
Koh Y, Jang B, Han SW, et al: Expression
of class III beta-tubulin correlates with unfavorable survival
outcome in patients with resected non-small cell lung cancer. J
Thorac Oncol. 5:320–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Séve P, Lai R, Reiman T, et al: Class III
beta-tubulin expression and benefit from adjuvant
cisplatin/vinorelbine chemotherapy in operable non-small-cell lung
cancer: analysis of NCIC JBR.10. Clin Cancer Res. 13:994–999.
2007.PubMed/NCBI
|
|
15.
|
Séve P, Isaac S, Trédan O, et al:
Expression of class III β-tubulin is predictive of patient outcome
in patients with non-small cell lung cancer receiving
vinorelbine-based chemotherapy. Clin Cancer Res. 11:5481–5486.
2005.
|
|
16.
|
Reiman T, Lai R, Veillard AS, et al:
Cross-validation study of class III beta-tubulin as a predictive
marker for benefit from adjuvant chemotherapy in resected
non-small-cell lung cancer: analysis of four randomized trials. Ann
Oncol. 23:86–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Stengel C, Newman SP, Leese MP, Potter BV,
Reed MJ and Purohit A: Class III beta-tubulin expression and in
vitro resistance to microtubule targeting agents. Br J Cancer.
102:316–324. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hansch C and Verma RP: Understanding
tubulin/microtubule-taxane interactions: a quantitative
structure-activity relationship study. Mol Pharm. 5:151–161. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Singer S, Malz M, Herpel E, et al:
Coordinated expression of stathmin family members by far upstream
sequence element-binding protein-1 increases motility in non-small
cell lung cancer. Cancer Res. 69:2234–2243. 2009. View Article : Google Scholar
|
|
20.
|
Pu X, Wang J, Xu L, et al: Relationship
between expression of beta-tubulin-III plus stathmin in advanced
non-small cell lung cancer and its sensitivity to venorelbine
chemotherapy. Zhongguo Fei Ai Za Zhi. 12:49–53. 2009.(In
Chinese).
|
|
21.
|
Singer S, Malz M, Herpel E, et al:
Coordinated expression of stathmin family members by far upstream
sequence element binding protein-1 increases motility in non-small
cell lung cancer. J Cancer Res. 69:2234–2243. 2009. View Article : Google Scholar : PubMed/NCBI
|
